Introduction
============

Obstructive sleep apnea (OSA), a condition that affects up to a quarter of the American adult population, remains largely unrecognized, and less than 5% of all OSA patients receive treatment ([@b143-vhrm-4-1327], [@b144-vhrm-4-1327]). Raising awareness among medical practitioners, and cardiologists in particular, about the high prevalence of unrecognized OSA is of great importance considering that OSA is an independent and potentially reversible risk factor for hypertension, myocardial ischemia and stroke ([@b95-vhrm-4-1327]; [@b96-vhrm-4-1327]; [@b141-vhrm-4-1327]; [@b145-vhrm-4-1327]). Increased cardiovascular morbidity in patients with untreated OSA is attributed to accelerated atherosclerosis ([@b59-vhrm-4-1327]; [@b54-vhrm-4-1327]; [@b28-vhrm-4-1327], [@b29-vhrm-4-1327]; [@b83-vhrm-4-1327]; [@b105-vhrm-4-1327]; [@b107-vhrm-4-1327]). The initial stimulus that triggers accelerated atherogenesis has not been definitively established.

Impaired endothelial function plays an important role in the development of cardiovascular manifestations of OSA. Normal endothelium regulates vasomotor tone and preserves inflammatory and coagulation homeostasis ([@b1-vhrm-4-1327]). These functions are altered in patients with OSA compared with healthy subjects ([@b16-vhrm-4-1327]; [@b89-vhrm-4-1327]; [@b59-vhrm-4-1327]; [@b30-vhrm-4-1327], [@b31-vhrm-4-1327]; [@b54-vhrm-4-1327]; Nieto et al 2004; [@b56-vhrm-4-1327]). Reduced numbers of endothelial progenitor cells and increased endothelial cell apoptosis in untreated OSA indicate impaired endothelial repair capacity ([@b33-vhrm-4-1327], [@b34-vhrm-4-1327]; [@b56-vhrm-4-1327]; [@b77-vhrm-4-1327]). In addition, increased sympathetic nervous activity may also contribute to cardiovascular morbidity in OSA ([@b86-vhrm-4-1327]; [@b78-vhrm-4-1327]). However, the reversibility of autonomic alterations with OSA-specific therapy remains controversial ([@b85-vhrm-4-1327]; [@b35-vhrm-4-1327]; [@b82-vhrm-4-1327]).

Repetitive hypoxia/reoxygenation associated with transient cessation of breathing during apneas and hypopneas is considered the main culprit for the impairment of endothelial function in OSA. Repetitive arousals resulting in sleep fragmentation and chronic sleep deprivation may also contribute to vascular dysfunction in OSA. Lastly, individual genetic susceptibility may play a role in development of cardiovascular manifestations of untreated OSA. The present review will focus on possible mechanisms of endothelial dysfunction in OSA.

Repetitive hypoxia/reoxygenation
================================

Repetitive hypoxia/reoxygenation during transient cessation of breathing as occurs in OSA resembles ischemia/reperfusion injury. Although perfusion remains intact during obstructive events in OSA, alterations involving generation of reactive oxygen species, inflammation and reduced nitric oxide (NO) availability are similar to those observed in models of ischemia-reperfusion ([@b73-vhrm-4-1327]; [@b133-vhrm-4-1327]; [@b59-vhrm-4-1327]; [@b66-vhrm-4-1327]; [@b30-vhrm-4-1327]; [@b121-vhrm-4-1327]; [@b63-vhrm-4-1327]; [@b54-vhrm-4-1327]; [@b83-vhrm-4-1327]; [@b4-vhrm-4-1327]).

Endothelial nitric oxide availability
-------------------------------------

Indirect evidence such as impaired flow-mediated brachial arterial dilation and decreased circulating NO levels measured by serum nitrite/nitrate suggest reduced NO availability in OSA patients ([@b59-vhrm-4-1327]; [@b53-vhrm-4-1327], [@b54-vhrm-4-1327]; [@b87-vhrm-4-1327]). Plasma levels of an endogenous inhibitor of endothelial nitric oxide synthase (eNOS) are increased and correlate inversely with flow-mediated dilation in patients with untreated OSA ([@b90-vhrm-4-1327]). Plasma levels of [l]{.smallcaps}-arginine, the substrate for NO production, increase after a single night of CPAP therapy in patients with OSA ([@b68-vhrm-4-1327]). Decreased eNOS activity and increased nitrotyrosine production, a byproduct of nitric oxide degradation, in freshly harvested venous endothelial cells provide direct evidence that nitric oxide bioavailability is reduced in OSA patients without overt cardiovascular disease ([@b56-vhrm-4-1327]).

Expression and activity of eNOS, a main source of basal endothelial NO, have been reported to be upregulated ([@b5-vhrm-4-1327]; [@b71-vhrm-4-1327]; [@b21-vhrm-4-1327]; [@b111-vhrm-4-1327]), downregulated ([@b80-vhrm-4-1327]; [@b73-vhrm-4-1327]; [@b97-vhrm-4-1327]; [@b65-vhrm-4-1327]; [@b126-vhrm-4-1327]; [@b121-vhrm-4-1327]), or unchanged ([@b84-vhrm-4-1327]; Tahawi et al 2007) in various experimental models of hypoxia and repetitive hypoxia/reoxygenation. Contradictory reports of eNOS expression and activity appear to be due to temporal variations in experimental hypoxemic conditions, and differences in the species and vascular bed from which endothelial cells were derived. Long-term intermittent hypoxia that mimicked OSA, administered in 30-second cycles for 6--8 hours daily for 35 days, resulted in elevated diurnal resting mean arterial blood pressure in rats ([@b36-vhrm-4-1327]; Tahawi et al 2007). Attenuated vasodilation in response to acetylcholine, a vasodilator that stimulates endothelial release of NO, and greater vasoconstriction with the NOS inhibitor N^G^-nitro-[l]{.smallcaps}-arginine methyl ester in rats exposed to long-term hypoxia/reoxygenation compared with controls, suggest decreased NO availability (Tahawi et al 2007). After prolonged hypoxia, eNOS activity is reduced ([@b61-vhrm-4-1327]; [@b121-vhrm-4-1327]), resulting in impaired vascular reactivity ([@b22-vhrm-4-1327]).

Several mechanisms of hypoxia-induced eNOS down-regulation have been proposed ([@b21-vhrm-4-1327]; [@b120-vhrm-4-1327]). On a transcriptional level, hypoxia-induced activation of hypoxia inducible factor-2 initially upregulates eNOS mRNA followed by a prolonged decrease in eNOS mRNA level ([@b21-vhrm-4-1327]). On a post-transcriptional level, hypoxia destabilizes eNOS mRNA, in part via the Rho kinase pathway in human venous and pulmonary artery endothelial cells ([@b121-vhrm-4-1327]). Hypoxia increases arginase II activity in endothelial cells, which degrades [l]{.smallcaps}-arginine, an essential substrate for NO production by eNOS ([@b20-vhrm-4-1327]). Oxidation of the eNOS cofactor tetrahydrobiopterin (BH~4~) by reactive oxygen species such as peroxynitrite appears to be an important mechanism linking oxidative stress to endothelial dysfunction ([@b63-vhrm-4-1327]; [@b4-vhrm-4-1327]). Decreased BH~4~ availability promotes superoxide production by eNOS, an altered enzyme state labeled "uncoupling" ([@b129-vhrm-4-1327]; [@b138-vhrm-4-1327]). Exposure to hypoxia for 24 hours leads to a time-dependent decrease in eNOS activator heat shock protein 90 that correlates with a decrease in eNOS activity in pulmonary artery endothelial cells ([@b42-vhrm-4-1327]; [@b116-vhrm-4-1327]). In contrast to short-term exposure to oxidative stress, prolonged oxidative stress as observed in untreated OSA reduces eNOS activity by suppressing its phosphorylation ([@b125-vhrm-4-1327]; [@b124-vhrm-4-1327]). Reduced NO availability results in endothelial dysfunction and thereby increases the risk for vascular diseases in patients with OSA.

Endothelial and systemic inflammation
-------------------------------------

Elevated levels of plasma C-reactive protein ([@b110-vhrm-4-1327]), leukocyte superoxide ([@b108-vhrm-4-1327]; [@b30-vhrm-4-1327]) and soluble adhesion molecules ([@b89-vhrm-4-1327]) suggest the presence of chronic systemic inflammation in OSA patients. Upregulation of cyclooxygenase-2 (COX-2) and inducible NOS in venous endothelial cells harvested from patients with untreated OSA provides direct evidence of vascular inflammation in OSA ([@b56-vhrm-4-1327]).

Accumulation and adhesion of circulating leukocytes to the vascular endothelium lead to vessel inflammation and progression of atherosclerosis ([@b100-vhrm-4-1327]; [@b1-vhrm-4-1327]). Monocyte expression of the adhesion molecules CD15 and CD11c is increased in patients with OSA compared with controls matched for age and cardiovascular comorbidities, although not BMI ([@b30-vhrm-4-1327]). Enhanced oxidative stress and adhesion to cultured endothelial cells in monocytes collected in the morning from OSA patients suggest an adverse effect of OSA on diurnal vascular proinflammatory/antiinflammatory homeostasis ([@b30-vhrm-4-1327]). Lymphocytic production of interleukin-4 (IL-4), a proinflammatory cytokine, is greater, while production of IL-10, a potent antiinflammatory cytokine, is decreased in otherwise healthy patients with moderate to severe OSA, compared with subjects with an AHI \<10/h ([@b31-vhrm-4-1327]).

Hypoxia/reoxygenation increases COX-2 gene and protein expression in endothelial cells in vivo and in vitro ([@b26-vhrm-4-1327]; [@b72-vhrm-4-1327]; [@b137-vhrm-4-1327]). Although COX-2 is widely accepted as a proinflammatory agonist, its upregulation can be cardioprotective in ischemia-reperfusion injury ([@b11-vhrm-4-1327]). In addition, the use of COX-2 inhibitors may result in an increased incidence of cardiovascular events ([@b3-vhrm-4-1327]). COX-2 appears to have a dual role in inflammation: initially inducing the inflammatory process and later aiding its resolution ([@b43-vhrm-4-1327]). Upregulation of COX-2 in OSA may result in increased oxidative stress caused by superoxide production and increased vasoconstrictor and/or inflammatory prostanoid production leading to increased platelet activation and endothelial dysfunction ([@b3-vhrm-4-1327]). Alternatively, induction of endothelial COX-2 in OSA patients may be a defense mechanism against repetitive hypoxia/reoxygenation.

Experimental models of repetitive hypoxia/reoxygenation that mimic OSA suggest that the proinflammatory transcription factor NF-κB is activated selectively over the hypoxia-inducible factor-1 (HIF-1) adaptive pathway in cultured endothelial cells, suggesting a maladaptive response to hypoxic stimulus in OSA ([@b104-vhrm-4-1327]; [@b47-vhrm-4-1327]). NF-κB upregulates several proinflammatory genes, including tumor necrosis factor-alpha (TNF-α) and IL-6 ([@b134-vhrm-4-1327]). Circulating levels of IL-6 and TNF-α are consistently elevated in patients with OSA, independently from central obesity ([@b2-vhrm-4-1327]). The initial sensing and signaling event for NF-κB activation remains unknown since it does not appear to be influenced by oxidative stress ([@b51-vhrm-4-1327]). In contrast, other investigators reported elevated levels of vascular endothelial growth factor (VEGF) and nocturnal erythropoietin, both mediated by the HIF-1 pathway, suggesting HIF-1 activation in patients with OSA ([@b67-vhrm-4-1327]; [@b136-vhrm-4-1327]). Since hypertension is associated with elevated VEGF concentrations, these discrepancies regarding activation of the adaptive HIF-1 pathway in OSA may be due to the coexistence of hypertension in some OSA patients ([@b127-vhrm-4-1327]). Alternatively, similar to COX-2 upregulation, VEGF upregulation may be an adaptive response to repetitive hypoxia/reoxygenation in OSA ([@b112-vhrm-4-1327]; [@b38-vhrm-4-1327]; [@b76-vhrm-4-1327]; [@b27-vhrm-4-1327]).

Insummary,endothelialproinflammatory/antiinflammatory homeostasis is shifted toward vascular inflammation in patients with untreated OSA.

Endothelial oxidative stress
----------------------------

Recent studies have demonstrated increased lipid peroxidation and generation of reactive oxygen species (ROS) by blood cells in OSA ([@b8-vhrm-4-1327]; [@b18-vhrm-4-1327], [@b19-vhrm-4-1327]; [@b70-vhrm-4-1327]; [@b57-vhrm-4-1327]; [@b142-vhrm-4-1327]; [@b123-vhrm-4-1327]). Vasoreactivity in OSA can be improved by antioxidants such as ascorbate and allopurinol, suggesting that oxidative stress contributes to endothelial dysfunction ([@b32-vhrm-4-1327]; [@b46-vhrm-4-1327]). The reoxygenation/reperfusion phase of the hypoxia/reoxygenation cycle appears to promote production of ROS leading to oxidative stress in OSA ([@b23-vhrm-4-1327]; [@b99-vhrm-4-1327]; [@b68-vhrm-4-1327]). Short-term intermittent hypoxia enhances cardiac susceptibility to ischemia/reperfusion injury in mice whereas longer exposure does not, suggesting temporal variation in response to oxidative stress ([@b92-vhrm-4-1327]). Repetitive episodes of hypoxia/reoxygenation increase production of reactive oxygen species in experimental models ([@b80-vhrm-4-1327]; [@b73-vhrm-4-1327]). Exposure of lean rodents to repetitive hypoxia/reoxygenation increases lipid peroxidation and decreases tissue-scavenging mechanisms in both heart and brain tissues ([@b140-vhrm-4-1327]; [@b17-vhrm-4-1327]). Super-oxide rapidly scavenges NO, generating peroxynitrate, a toxic metabolite that nitrosylates tyrosine residues, forming nitrotyrosine, a marker of oxidative stress ([@b62-vhrm-4-1327]). Levels of circulating free nitrotyrosine are similar in patients with OSA and healthy subjects ([@b117-vhrm-4-1327]). In contrast, expression of nitrotyrosine in endothelial cells harvested from otherwise healthy patients with OSA is greater than controls, suggesting enhanced endothelial oxidative stress ([@b56-vhrm-4-1327]). Endothelial expression of nitrotyrosine more closely reflects endothelial oxidative stress in OSA than levels of circulating free nitrotyrosine since the in vivo half-life of nitrotyrosine is short, and its volume of distribution is 20-fold greater than the plasma volume indicating its extensive distribution in the extravascular compartment ([@b118-vhrm-4-1327]). As endothelial oxidative stress increases and fewer cofactors are available for nitric oxide synthesis, eNOS preferentially promotes superoxide production, thereby perpetuating a vicious cycle of endothelial injury ([@b129-vhrm-4-1327]; [@b138-vhrm-4-1327]; [@b66-vhrm-4-1327]).

Repetitive hypoxia/reoxygenation promotes endothelial apoptosis by activating cell death receptors and mitochondria-dependent apoptotic pathways ([@b24-vhrm-4-1327]; [@b146-vhrm-4-1327]). Exposure of rat aortic rings to increasing concentrations of isolated endothelial apoptotic microparticles derived from cultured endothelial cells or patients with myocardial ischemia alters endothelium-dependent vasodilation and nitric oxide production while simultaneously increasing superoxide production ([@b13-vhrm-4-1327]; [@b14-vhrm-4-1327]). Furthermore, increased concentrations of endothelial apoptotic microparticles impair angiogenesis in vitro ([@b14-vhrm-4-1327]).

Thus, repetitive hypoxia/reoxygenation as observed in OSA adversely impacts endothelial function by promoting oxidative stress and inflammation, and reducing nitric oxide availability.

Sleep fragmentation and deprivation
===================================

Chronic sleep deprivation is associated with a 50% decline in endothelium-dependent vasodilation in healthy subjects suggesting reduced NO availability ([@b122-vhrm-4-1327]). Levels of pro-inflammatory markers such as C-reactive protein (CRP), IL-6, and TNF-α are elevated after partial and sustained sleep deprivation in healthy subjects ([@b81-vhrm-4-1327]; [@b130-vhrm-4-1327]; [@b55-vhrm-4-1327]; [@b49-vhrm-4-1327]). Levels of soluble TNF-α receptor 1 and IL-6 are elevated in healthy men after 4 days of sustained sleep deprivation, suggesting a role for sleep deprivation as a proinflammatory stimulus ([@b109-vhrm-4-1327]).

Sleep deprivation may alter coagulation homeostasis. Elevated levels of plasma D-dimer are associated with increased awake time after sleep onset in elderly subjects ([@b79-vhrm-4-1327]; [@b131-vhrm-4-1327]). Arousal index is correlated with plasma levels of von Willebrand's factor, a mediator of platelet adhesion ([@b132-vhrm-4-1327]). Wake after sleep onset time is correlated with levels of soluble tissue factor, an initiator of the coagulation cascade, after adjustment for AHI ([@b132-vhrm-4-1327]).

Based on available evidence, sleep deprivation alone does not appear to promote oxidative stress. Sleep deprivation does not affect oxidant production, antioxidant enzyme activity, lipid peroxidation or protein oxidation in brain, liver, and skeletal muscle in a rat model ([@b44-vhrm-4-1327]).

Chronic sleep deprivation is associated with greater prevalence of obesity that might itself increase cardiovascular risk in OSA. Sleep fragmentation, assessed with actigraphy, is associated with higher BMI and risk of obesity in community-dwelling elderly ([@b128-vhrm-4-1327]). Acute partial sleep deprivation reduces levels of leptin, a hormone regulating satiety and energy homeostasis, elevates levels of ghrelin, a hormone associated with appetite, and increases subjective sensation of hunger, creating a weight-gaining phenotype in healthy subjects ([@b114-vhrm-4-1327]). Compared with longer sleep duration, self-reported sleep duration of ≤5 hours was associated with incident diabetes in 8992 subjects followed over 8--10 years (odds ratio = 1.5) ([@b41-vhrm-4-1327]). Self-reported reduced sleep duration in 70,000 participants in the Nurses Health Study was associated with increased cardiovascular risk over a 10-year period after adjustment for age, snoring and BMI ([@b6-vhrm-4-1327]). Acute sleep deprivation of healthy young men and women is associated with increased p-wave dispersion on electrocardiography, an electrophysiologic marker for the prediction of paroxysmal atrial fibrillation ([@b25-vhrm-4-1327]; [@b106-vhrm-4-1327]). In addition, OSA itself has been associated with increased p-wave dispersion and incidence of atrial fibrillation ([@b39-vhrm-4-1327]; [@b15-vhrm-4-1327]). Sustained sleep deprivation for 36 h increased sympathetic and decreased parasympathetic activity as measured by heart rate and blood pressure variability ([@b147-vhrm-4-1327]). Sleep deprivation-induced elevated sympathetic activity may contribute to adverse cardiovascular outcomes in OSA.

In summary, chronic sleep deprivation associated with OSA may potentiate the adverse effects of hypoxia/reoxygenation on cardiovascular function.

Genetic contributions
=====================

Genetic susceptibility for cardiovascular manifestations of OSA may be mediated by gene polymorphisms associated with regulation of body weight, lipid metabolism, inflammatory response and autonomic vascular function ([@b60-vhrm-4-1327]; [@b58-vhrm-4-1327]; [@b91-vhrm-4-1327]; [@b45-vhrm-4-1327]; [@b103-vhrm-4-1327]; Borgel et al 2006; [@b98-vhrm-4-1327]). OSA patients with and without coexistent coronary artery disease are more likely to have a family history of premature cardiovascular death than those without OSA, after adjustment for BMI ([@b40-vhrm-4-1327]). In a murine model of OSA, genetic background determines both the pattern and magnitude of the chronotropic response to apnea ([@b52-vhrm-4-1327]). Apolipoprotein E epsilon4 (ApoE epsilon4) is a well-known risk factor for cardiovascular disease ([@b113-vhrm-4-1327]; [@b10-vhrm-4-1327]). The APOE epsilon4 allele is associated with increased risk of OSA, particularly in individuals under age 65 ([@b58-vhrm-4-1327]; [@b45-vhrm-4-1327]).

Along with male gender, obesity is the strongest risk factor for the development of OSA ([@b93-vhrm-4-1327]). Obesity explains nearly 40% of the genetic heritability of OSA in a large cohort of 310 families with OSA ([@b94-vhrm-4-1327]). Levels of ghrelin, a hormone associated with appetite, decline to near normal levels following short-term CPAP therapy in obese OSA patients without concomitant change in body weight, suggesting that OSA itself promotes ghrelin production ([@b50-vhrm-4-1327]).

The G-allele of a single nucleotide polymorphism in the pro-inflammatory IL-6 gene is associated with 6-fold increased odds of having OSA after adjustment for obesity ([@b64-vhrm-4-1327]). Increased prevalence of the TNF-α (--308A) polymorphism, a genotype associated with increased production of the pro-inflammatory cytokine TNF-α, in OSA patients compared with population controls may reflect a propensity for enhanced inflammatory response to repetitive hypoxia/reoxygenation and sleep deprivation associated with OSA ([@b135-vhrm-4-1327]; [@b103-vhrm-4-1327]).

Reports of an association between angiotensin-converting enzyme (ACE) polymorphisms and OSA have been inconsistent. Treatment with an angiotensin II receptor blocker prevents elevation of blood pressure due to repetitive hypoxia/reoxygenation in an animal model of OSA ([@b37-vhrm-4-1327]). The D allele and in particular the DD genotype of the ACE gene is associated with the development of hypertension and may confer an increased risk of cardiovascular disease ([@b88-vhrm-4-1327]; [@b9-vhrm-4-1327]; [@b60-vhrm-4-1327]). OSA increases the risk of hypertension, particularly in male carriers of the ACE gene D allele ([@b74-vhrm-4-1327]; [@b12-vhrm-4-1327]). However, other investigators reported no significant correlation between AHI and ACE activity in OSA patients ([@b139-vhrm-4-1327]; Barcelo et al 2001).

Summary
=======

Endothelial dysfunction and inflammation mediate the cardiovascular manifestations of OSA. Repetitive hypoxia/reoxygenation, as observed in OSA, adversely impacts endothelial function by promoting oxidative stress and inflammation, and reducing NO availability. Sleep fragmentation and deprivation may potentiate hypoxia/reoxygenation injury by independently promoting vascular inflammation and procoagulability. Genetic susceptibility for cardiovascular manifestations of OSA may be mediated by gene polymorphisms associated with regulation of body weight, lipid metabolism, inflammatory response and autonomic vascular function.
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